Translation of biomedical materials
Post author: Julie Rothacker. Last update: 01/07/2016 at 11:01 am by Julie Rothacker.
The Biomedical Materials Translational Facility (BMTF) is led by Monash University and CSIRO in partnership with Monash Health Translation Precinct (MHTP) and the Australian Nuclear Science and Technology Organisation (ANSTO). Its aim is to foster rapid progress in materials and biomedical sciences and assist in commercialising the next generation of medical devices, diagnostics and cell therapies. This initiative is supported by the Science and Industry Endowment Fund (SIEF).
Capabilities include clean room materials synthesis, fabrication and surface coating, high throughput biological testing and evaluation of materials and real-time non-invasive imaging for pre-clinical studies.
It will allow discoveries to be accelerated through the next phases of scale-up, prototype evaluation and biological testing. Importantly and uniquely, it will provide this suite of equipment within appropriate GMP and clean room facilities. This will enable new materials and processes to be developed within the framework needed for subsequent in vivo evaluation and adoption by industry partners. The co-location of these activities brings together in one place the range of specialist multidisciplinary expertise necessary for biomedical innovation, and fosters rapid translation of new technologies. It also provides an environment for translational research, allowing strong fundamental research expertise to be brought to bear in the development of new approaches to biomedical manufacturing, such as 3D printing or bioactive coating technologies.
Assay development, Bio-Assay, Biocontainment (PC3 and PC4), Cells and tissues, Clean rooms, Clinical Trials Design and Managment, Clinical trials resources, Design and Prototyping, Devices, Manufacturing, MRI, Mulit-modal, Nanofabrication, PET, Preclinical assays, Production, Safety and efficacy, Tissues preparationBiological Science categories: